DOD Deployment Related Medical Hypothesis Development Award

The summary for the DOD Deployment Related Medical Hypothesis Development Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

DOD Deployment Related Medical Hypothesis Development Award: The DRMRP Hypothesis Development Award is being offered for the first time in FY08.The intent of this award is to provide support for initial exploration of innovative, untested, potentially groundbreaking concepts that may lead to promising new products, pharmacologic agents (drugs or biologics), behavioral interventions, devices, clinical guidance, and/or emerging approaches and technologies for deployment-related health care issues within the FY08 DRMRP topic areas. Innovation and novelty of concept are important aspects of this award mechanism. Results of studies conducted through a Hypothesis Development Award may provide the scientific rationale on which a new hypothesis can be based or it may provide initial proof-of-principle of an innovative hypothesis. Because this award is designed to provide investigators with the opportunity to pursue serendipitous observations, some gaps in supporting rationale may exist due to lack of available information. The award mechanism is not intended to support ongoing work. Therefore, the existence of preliminary data suggests that the research proposal should be submitted to a different award mechanism. Successfully completed Hypothesis Development Awards are expected to lead to research endeavors that will garner funding through the CDMRP or other funding agencies. It is the responsibility of the PI to clearly and explicitly articulate the projects innovation.Members of each review panel will be blinded to the identity of the PI and the PIs institution. Due to the blinded nature of the review process, references to the PI or the institution in the project narrative and/or the military relevance statement are prohibited and will result in administrative withdrawal of the proposal. In addition, the use of "I," "our," "this institution," or similar phrases that make it possible to identify the PI and/or institution through the references listed will result in administrative withdrawal of the proposal.Use of human subjects and human biological substances: Because these awards are designed for preliminary investigations, projects involving human subjects or specimens will not be supported unless they are exempt under Title 32, Code of Federal Regulations, Part 219, Section 101(b)(32 CFR 219.101(b)). Studies that do not qualify for exempt status will be administratively withdrawn and will not be funded. For studies using only commercially available unidentified specimens, a Claim of Exemption Form will be requested. Additional information regarding exempt status may be found on the USAMRMC Human Research Protection Office website (https://mrmc.amedd.army.mil/rodorphrpo.asp).This award may not be used to conduct clinical trials. PIs seeking funding for a clinical trial should apply to the Clinical Trial Award mechanism.See the Program Announcement for the full Funding Opportunity Description.